Form 483

Apozeal Pharmaceuticals Inc. Form 483, 2018-07-26

FDA issued a Form 483 to Apozeal Pharmaceuticals Inc. on 2018-07-26 with 4 public-safe observations.

483· Form 483 issuedHuman Drugs4 observations

Apozeal Pharmaceuticals Inc. · Levittown, United States · Issued July 26, 2018

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

26 Jul 2018
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Anastasia M Shields, Christina K Theodorou

26 Jul 2018
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Anastasia M Shields, Christina K Theodorou

26 Jul 2018
21 CFR 211.192

Written record of investigation incomplete

Cited by Anastasia M Shields, Christina K Theodorou

26 Jul 2018
21 CFR 211.67(b)(3)

Cleaning SOPs/instructions

Cited by Anastasia M Shields, Christina K Theodorou

Inspected site

APApozeal Pharmaceuticals Inc.Levittown, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)(3)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 4 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere